Ultragenyx Pharmaceutical (RARE) Share-based Compensation (2013 - 2026)
Ultragenyx Pharmaceutical (RARE) posted quarterly Share-based Compensation of $30.0 million for Q1 2026, down 25.0% year-over-year from $40.0 million in Q1 2025, and down 19.55% quarter-over-quarter from $37.3 million in Q4 2025.
Ultragenyx Pharmaceutical (RARE) Share-based Compensation (2013 - 2026) Analysis & Trends
Ultragenyx Pharmaceutical (RARE) has reported Share-based Compensation for 14 consecutive years, with $30.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Share-based Compensation fell 25.0% year-over-year to $30.0 million; the TTM figure through Mar 2026 stood at $142.9 million (down 11.27% YoY), while the FY2025 annual figure was $153.0 million, down 3.16% from the prior year.
- Share-based Compensation fell to $30.0 million in Q1 2026 per RARE's latest filing, from $37.3 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $41.6 million in Q3 2024 and bottomed at $1.6 million in Q1 2022.
- Historically, Share-based Compensation has averaged $30.3 million across 5 years, with a median of $35.8 million in 2022.
- Annual changes were most pronounced in 2022 — Share-based Compensation slumped 93.49% — and 2025, when it jumped 1335.75%.
- Ultragenyx Pharmaceutical's Share-based Compensation stood at $29.4 million in 2022, then increased by 14.23% to $33.5 million in 2023, then gained by 19.69% to $40.1 million in 2024, then slipped by 7.09% to $37.3 million in 2025, then slipped by 19.55% to $30.0 million in 2026.
- Business Quant data shows RARE's Share-based Compensation at $30.0 million in Q1 2026, $37.3 million in Q4 2025, and $37.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Ultragenyx Pharmaceutical | 2.61 Bn | 2.33 Bn | 180.00 Mn | 34.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 34.00 Mn |
| Jun 30, 2026 | 34.00 Mn |
| Mar 31, 2026 | 30.00 Mn |
| Mar 31, 2026 | 30.00 Mn |
| Dec 31, 2025 | 37.29 Mn |
| Dec 31, 2025 | 37.29 Mn |
| Sep 30, 2025 | 37.01 Mn |
| Sep 30, 2025 | 37.01 Mn |
| Jun 30, 2025 | 38.62 Mn |
| Jun 30, 2025 | 38.62 Mn |
| Mar 31, 2025 | 40.00 Mn |
| Mar 31, 2025 | 40.00 Mn |
| Dec 31, 2024 | 40.13 Mn |
| Dec 31, 2024 | 40.13 Mn |
| Sep 30, 2024 | 41.57 Mn |
| Sep 30, 2024 | 41.57 Mn |
| Jun 30, 2024 | 39.36 Mn |
| Jun 30, 2024 | 39.36 Mn |
| Mar 31, 2024 | 2.79 Mn |
| Mar 31, 2024 | 2.79 Mn |